Baldness patterns, genetics, and risk for prostate cancer

According to a newly-published study in the Journal of Clinical Oncology, certain types of male baldness are associated with a heightened risk for aggressive forms of prostate cancer (but this finding really needs to be confirmed in other studies). … READ MORE …

D’Amico on the individualization of prostate cancer risk management

In an interesting article in the September 2014 issue of The ASCO Post, Dr. Anthony D’Amico argues in favor of a future in which individualized approaches to risk will replace PSA screening alone as a means of determining who actually needs to be biopsied and (if necessary) receive treatment for clinically significant prostate cancer. … READ MORE …

Cancer screening re-visited again

An article by Melinda Beck in today’s issue of The Wall Street Journal discusses the complex topic of screening, “over-diagnosis”, and over-treatment of low-risk forms of certain cancers (prostate cancer specifically included). … READ MORE …

Metabolic aberrations and risk for prostate cancer

According to a newly published study of data from > 285,000 European males (the Metabolic Syndrome and Cancer Project), men with metabolic aberrations are at slightly less risk for a diagnosis of prostate cancer compared with men who have normal levels of metabolic factors … but their risk for prostate cancer-specific mortality is similar. … READ MORE …

“There’s a sponge in my prostate, dear doctor, dear doctor”

About once in every 5,500 to 7,000 surgical operations carried out in hospitals around America each year, “something” gets left behind in a patient … and that “something” is most likely to be one of those small surgical sponges used to mop up excess blood or other fluids during the course of the operation. … READ MORE …

Denosumab therapy and risk for severe hypocalcemia

Denosumab — marketed as Xgeva and as Prolia — is associated with a rare but well-known risk for severe hypocalcemia (very low calcium in the blood stream). Denosumab, when give as Xgeva,  is specifically indicated for the prevention of skeletal-related events in patients with bone metastases from prostate and other forms of cancer. … READ MORE …

The less you know, the harder the decisions about treatment …

In one more of those utterly unsurprising research findings, a study of newly diagnosed patients has shown that poor patient knowledge about the nature of prostate cancer is associated with “decisional conflict” leading to stress and anxiety given the uncertainty associated with the relative “value” of the many possible management options. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,142 other followers